Home/Pipeline/TSND-201 (Methylone)

TSND-201 (Methylone)

Post-Traumatic Stress Disorder (PTSD)

Phase 2Active

Key Facts

Indication

Post-Traumatic Stress Disorder (PTSD)

Phase

Phase 2

Status

Active

Company

Transcend Therapeutics

About Transcend Therapeutics

Transcend Therapeutics is a private, New York-based biotech founded in 2021, operating in the psychedelics-derived therapeutics sector. The company has achieved significant clinical and regulatory milestones, including Breakthrough Therapy Designation from the FDA for its lead program, TSND-201, for PTSD, and has recently agreed to be acquired by Otsuka Pharmaceutical. Its strategy centers on developing rapid-acting, neuroplasticity-promoting (neuroplastogen) drugs that offer a novel mechanism of action compared to standard-of-care antidepressants and anxiolytics. With promising Phase 2 data published in a top-tier journal, Transcend is positioned as a key player in the next generation of mental health therapeutics.

View full company profile

Therapeutic Areas

Psychiatry Neurology

Other Post-Traumatic Stress Disorder (PTSD) Drugs

Drug	Company	Phase	Status
AL001	Alzamend Neuro	Preclinical	Research
PES200	Virpax Pharmaceuticals	Discovery/Preclinical	Active
Sequential Dialysis Technique	Halberd	Discovery	Active Research (Gov't Funding Sought)
NeuroDirect™ Ketamine	Psycheceutical Bioscience	Phase 1	Active
Sana Device for PTSD	Sana Health	Pilot/Proof-of-Concept	Active
MDMA-assisted therapy	Lykos Therapeutics	Phase 3	Active
Neuroplastogen Programs	Delix Therapeutics	Pre-clinical	Active
Phoenix CR	Evren Technologies	Unknown	Active
Lu AG09222	Lundbeck	Phase 2	Active
COMP360 Psilocybin Therapy	Compass Pathways	Phase 2	Active
NRX-101	NRx Pharmaceuticals	Phase 2	Investigational
Ketamir-2 (Ketamir)	MIRA Pharmaceuticals	Phase 1	Active